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Two series of benzimidazole derivatives were sythesised. The first one was based on
5,6-dinitrobenzimidazole, the second one comprises 2-thioalkyl- and thioaryl-sub-
stituted modified benzimidazoles. Antibacterial and antiprotozoal activity of the
newly obtained compounds was studied. Some thioalkyl derivatives showed remark-
able activity against nosocomial strains of Stenotrophomonas malthophilia, and an ac-
tivity comparable to that of metronidazole against Gram-positive and Gram-negative
bacteria. Of the tested compounds, 5,6-dichloro-2-(4-nitrobenzylthio)-benzimidazole
showed the most distinct antiprotozoal activity.
Benzimidazole derivatives are of wide inter-
est because of their diverse biological activity
and clinical applications [1]. This ring system
is present in numerous antiparasitic, fungi-
cidal, anithelemintic and anti-inflammatory
drugs [2–5]. Also, some benzimidazole nu-
cleosides, particularly 5,6-dichlorobenzimi-
dazole-1--D-ribofuranoside (DRB) and its
2-substituted derivatives show activity
against human cytomegalovirus [6]. It is also
known that 5,6-dinitrobenzimidazole can sub-
stitute 5,6-dimethylbenzimidazole in the vita-
min B12 molecule in Corynebacterium di-
phteriae [7] and 2-trifluorobenzimidazoles are
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potent decouplers of oxidative phospho-
rylation in mitochondria. They are also inhibi-
tors of photosynthesis, and some exhibit ap-
preciable herbicidal activity [8]. Most re-
cently, antiprotozoal activity of substituted
2-trifluorobenzimidazoles has been reported
[9], consistent with several earlier studies on
the anti-giardial activity of various
benzimidazole derivatives [10, 11]. However,
the general antimicrobial activity of
benzimidazole derivatives has not been exten-
sively investigated. The earliest report of their
antibacterial activity appeared in 1964 [12],
and more recently we have found two groups
of substituted benzimidazoles, namely the
5,6-dinitro and 2-trifluoromethyl derivatives,
to be promising candidates for antimicrobial
drugs [13]. In this paper we present new data
on the antimicrobial and antiprotozoal activi-
ties of 5,6-dinitro and 2-dialkylaminosubsti-
tuted benzimidazoles.
MATERIALS AND METHODS
General methods. All chemicals and sol-
vents were purchased from Sigma-Aldrich.
Melting points (uncorr.) were measured in
open capillary tubes on a Gallenkamp-5 melt-
ing point apparatus. Ultraviolet absorption
spectra were recorded in a Kontron Uvikon
940 spectrophotometer. 1H-NMR spectra (in
ppm) were measured with a Varian Gemini
(200 MHz) and a Varian UNITY plus (500
MHz) spectrometer at 298 K in D6(Me2SO) us-
ing tetramethylsilane as internal standard.
Flash chromatography was performed with
Merck silica gel 60 (200–400 mesh). Analyti-
cal TLC was carried out on precoated silica gel
F254 (Merck) plates (0.25 mm thickness).
Analyses of the new compounds were within
±0.4% of the theoretical values.
Bacterial strains and drug susceptibility
assays. Bacteria were used as follows: Staphy-
lococcus aureus strains ATCC 6538P, ATCC
25923 and NCTC 4163; Bacillus subtilis ATCC
6633, Bacillus stearothermophilus ATCC 7953
and Bacillus cereus ML 98; Escherichia coli
NCTC 8196; Proteus vulgaris NCTC 4635;
Micrococcus flavus NCIB 8166.
Bacterial strains from Pseudomonadaceae
family: Pseudomonas aeruginosa ATCC 27863,
ATCC 15442 and NCTC 6749; Burkholderia
cepacia ATCC 25416; Stenotrophomonas
malthophilia ATCC 13637 and clinical isolates
— 67 strains of S. malthophilia were used. Bac-
terial strains were obtained from the State In-
stitute of Hygiene (Warszawa), the Medical
University, Warszawa and the Children’s Me-
morial Health Institute.
Antimicrobial activity was tested by the
disc-diffusion method under standard condi-
tions using Mueller-Hinton agar medium as
described by NCCLS [14]. Sterile filter paper
discs (9 mm diameter, Whatman No. 3 chro-
matography paper) were soaked in test com-
pound solutions prepared in EtOH/Me2SO
mixture (1:1, v/v) and finally contained
400 g of the compound per disc. The results
were read following 18–20 h incubation at
35C. MIC — the minimum inhibitory concen-
tration — was performed by the agar dilution
method according to guidelines established by
the NCCLS [15]. MIC was described as the
lowest concentration of the drug that visibly
inhibited growth. A single colony or faint haze
was regarded as no growth. MICs were inter-
preted after 18 and 42 h of incubation at
35C. Concentrations of agents in Muller-
Hinton II Agar medium (Becton Dickinson)
ranged from 12.5 to 400 g  cm–3. Agar
plates were inoculated using a replicator with
2 l volumes. The final inoculum of bacteria
was 10–4 CFU  cm–3. Solutions of the
agents tested were prepared in 0.125 M HCl,
for compounds 4d, 4f and 4n, and in a 0.125
M HCl/MeOH mixture (1:0.6, v/v) for com-
pound 4e.
Protozoan parasite isolates, culture and
drug susceptibility assays. Giardia duo-
denalis, Trichomonas vaginalis and Entamoeba
histolytica were grown in TYI-S-33 which was
supplemented with bile for Giardia [16]. Para-
sites were subcultured three times a week ex-
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cept for Entamoeba which was subcultured
twice a week [16]. T. vaginalis strain BRIS/
92/STDL/F1623 and the metronidazole re-
sistant line derived from it BRIS/92/STDL/
F1623-M1 (F1623-M1), E. histolytica strain
HTH-56:MUTM (MUTM) and G. duodenalis
strains BRIS/83/HEPU/ 106 (referred to as
106), the metronidazole-resistant line
BRIS/83/HEPU/106-2ID10 derived from 106
(106-2ID10), WB1B, the metronidazole-resis-
tant line WB-M3 and the albendazole resis-
tant line WB-M3-Alb (WB/Alb) are described
in [16]. Drug susceptibility assays were de-
tailed previously [16].
Syntheses
1-Substituted 5,6-dinitrobenzimidazoles.
5,6-Dinitro-1-(dimethylaminoeth-1-yl)benzimi-
dazole (2a): 1.05 g (5 mmol) of 5,6-dinitroben-
zimidazole (1) was dissolved in acetonitrile
(40 ml) containing 2.4 ml (16 mmol) 1,8-dia-
zabicyclo[5,4,0]undecen-7-en (DBU) followed
by addition of 0.864 g (6 mmol) of 2-dime-
thylaminoethylchloride hydrochloride. The
solution was stirred overnight at room tem-
perature and then refluxed for 1 h. The reac-
tion mixture was evaporated to dryness and
the residue was chromatographed on a silica
gel column (315 cm) with CHCl3 (200 ml),
followed by CHCl3/MeOH (95:5). The prod-
uct-containing fractions were evaporated and
the residue crystallized from ethyl ace-
tate/MeOH to give 2a (0.90 g, 64%); m.p.
173–177C; 1H NMR (D6-Me2SO)  (ppm):
2.16 (s, 2  CH3), 2.65 and 4.49 (2  t,
-CH2CH2-), 8.53, 8.72 and 8.75 (3s, H-2, H-4
and H-7). UV (H2O/MeOH, 1:1): 246 nm
(16900), 300 (sh, 6000). Elemental analysis:
calculated for C11H13N5O4: C, 47.30; H, 4.70;
N, 25.08. Found: C, 47.47; H, 4.61; N, 25.07.
5,6-Dinitro-1-(diethylaminoeth-1-yl)benzimi-
dazole (2b): Compound 2b was similarly syn-
thesised to the procedure described above for
2a, from 1 and 2-diethylaminoethylchloride
hydrochloride: (m.p. 123–127C, 49%); 1H
NMR (D6-Me2SO):  (ppm): 0.71 and 2.42 (t
and q, N-CH2CH3), 2.71 and 4.44 (2  t,
-CH2CH2-), 8.52, 8.70 and 8.73 (3s, H-2, H-4,
H-7). UV (H2O/MeOH, 1:1): 246 nm (18200),
300 (sh, 6000). Elemental analysis: calculated
for C13H17N5O4: C, 50.80; H, 5.59; N, 22.79.
Found: C, 50.92; H, 6.05; N, 22.62.
5,6-Dinitro-1-(dimethylaminoprop-1-yl)benzi-
midazole (2c): The synthesis was similar to
the procedure for 2a, from 1 and 3-dimethyl-
aminopropylchloride hydrochloride: (m.p.
232–235C, 38%); 1H NMR (D6-Me2SO): 
(ppm): 2.70 (s, 2  CH3), 2.24, 3.03 and 4.53
(2  t and m, -CH2CH2CH2-), 8.59, 8.79 and
8.87 (3s, H-2, H-4, H-7). UV (H2O/MeOH, 1:1):
246 nm (18200), 300 (sh, 6000). Elemental
analysis: calculated for C12H15N5O4: C, 49.13;
H, 5.17; N, 23.88. Found: C, 49.30; H, 5.19; N,
22.62.
5,6-Dinitro-1-(morpholineth-1-yl)benzimida-
zole (2d): Similar to 2a, from 1 and N-
(2-chloroeth-1-yl)morpholine hydrochloride:
(m.p. 166–169C, 42%); 1H NMR (D6-Me2SO)
 (ppm): 2.69 and 4.54 (2  t, -CH2CH2-), 2.42
and 3.48 (2  t, CH2-morpholine), 8.51, 8.71
and 8.75 (3s, H-2, H-4 and H-7). UV
(H2O/MeOH, 1:1): 247 nm (18500), 310 (sh,
6000). Elemental analysis: calculated for
C13H15N5O5: C, 48.59; H, 4.71; N, 21.80.
Found: C, 48.69; H, 4.86; N, 21.60.
5,6-Dinitro-1-(piperidineth-1-yl)benzimidazole
(2e): Similar to 2a, from 1 and N-(2-chlo-
roeth-1-yl)piperidine hydrochloride: (m.p.
206–208C, 26%); 1H NMR (D6-Me2SO) 
(ppm): 1.38 (m, CH2-piperidine), 2.63 and4.49
(2 t, -CH2CH2-), 8.53, 8.71 and 8.73 (3s, H-2,
H-4 and H-7). UV (H2O/MeOH, 1:1): 246 nm
(17200), 300 (sh, 6000). Elemental analysis:
calculated for C14H17N5O4: C, 52.65; H, 5.38;
N, 21.93. Found: C, 52.83; H, 5.52; N, 21.77.
5,6-Dinitro-1-(2-hydroxyeth-1-yl)benzimidazole
(2f): Similar to 2a, from 1 and 2-bromo-
ethanol: (m.p. 235–238C, 56%); 1H NMR
(D6-Me2SO)  (ppm): 3.75 and 4.46 (q and t,
-CH2CH2-), 8.53, 8.66 and 8.72 (3s, H-2, H-4
and H-7). UV (H2O/MeOH, 1:1): 247 nm
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(16500), 300 (sh, 6000). Elemental analysis:
calculated for C9H8N5O5: C, 42.86; H, 3.20; N,
22.22. Found: C, 42.99; H, 3.34; N, 22.01.
5,6-Dinitro-1-(2,3-dihydroxyprop-1-yl)benzimi-
dazole (2 g): Similar to 2a, from 1 and
glycitole: (m.p. 198–201C, 47%); 1H NMR
(D6-Me2SO)  (ppm): 3.32 (m, CH2-3), 4.35
(m, CH-2), 4.53 (dd, CH2-1), 4.91 (t, HO-3),
5.19 (d, HO-2), 8.53, 8.61 and 8.62 (3s, H-2,
H-4 and H-7); UV (H2O/MeOH, 1:1): 249 nm
(17200), 300 (sh, 7000). Elemental analysis:
calculated for C10H10N4O6: C, 42.55; H, 3.58;
N, 19.86. Found: C, 42.33; H, 3.45; N, 19,80.
S-alkylated and -arylalkylated deriva-
tives of C-substituted benzimidazoles
(4a–m). 2-(Dimethylaminoeth-1-ylthio)benzimi-
dazole (4a): 0.6 g (4 mmol) of 2-thioben-
zimidazole was dissolved in acetonitrile (20
ml) containing 2 ml (14 mmol) DBU followed
by the addition of 0.72 g (5 mmol) of
2-dimethylaminoethylchloride hydrochloride.
The solution was stirred overnight at room
temperature and the solvent evaporated. Wa-
ter (5 ml) was added to the residue and the
mixture was brought to pH 7 with CH3COOH.
The precipitate formed was filtered and crys-
tallized from H2O to give 4a (0.424 g, 48%);
m.p. 137–140C; 1H NMR (D6-Me2SO) 
(ppm): 2.41 (s, 2  CH3), 2.88 and 3.47 (2t,
-CH2CH2-), 7.10 and 7.44 (2m, H-benzimi-
dazole). UV (H2O, pH 7.0): 282 (10500), 289
(10300). Elemental analysis: calculated for
C11H15N3S: C, 59.70; H, 6.85; N, 18.99.
Found: C, 59.55; H, 6.66: N, 18.83.
5,6-Dimethyl-2-(dimethylaminoeth-1-ylthio)be-
nzimidazole (4b): Similar to 4a, from 3b and
2-dimethylaminoethylchloride hydrochloride.
The crude product was purified by silica gel
column chromatography (3  15 cm) using
CHCl3/MeOH (85:15) as an eluent. Crystalli-
zation from diethyl ether/petroleum ether
yielded 4b (340 mg, 39%); m.p. 135–137C; 1H
NMR (D6-Me2SO)  (ppm): 2.18 and 2.26 (2s,
2  CH3-benzimidazole and 2  N-CH3), 2.57
and 3.35 (2t, -CH2CH2-), 7.19 (s, H-4 and H-7).
UV, (H2O, pH 7.0): 291 (13500), 297 (13300).
Elemental analysis: calculated for C13H19-
N3S: C, 62.61; H, 7.70; N, 16.86. Found: C,
62.86; H, 7.55; N, 16.88.
5-Chloro-2-(dimethylaminoeth-1-ylthio)benzi-
midazole hydrochloride (4c): Similar to 4b,
from 3c and 2-dimethylaminoethylchloride
hydrochloride. Pure product was treated with
MeOH saturated with dry HCl to give 4c (m.p.
239–242C 42%); 1H NMR (D6-Me2SO) 
(ppm): 2.83 (s, 2  CH3), 3.48 and 3.74 (2t,
-CH2CH2-), 7.26 and 7.54 (2dd, H-6 and H-7),
7.61 (d, H-4). UV (H2O, pH 7.0): 251 (5600),
290 (12500), 298 (12300). Elemental analy-
sis: calculated for C11H14N3SClHCl: C,
45.21; H, 5.18; N, 14.38. Found: C, 45.12; H,
5.27; N, 14.50.
5,6-Dichloro-2-(dimethylaminoeth1-ylthio)be-
nzimidazole hydrochloride (4d): Similar to 4a,
from 3d and 2-dimethylaminoethylchloride
hydrochloride and transformed to hydrochlo-
ride analogously to the method given for 4c
(m.p. 193–195C, 44%); 1H NMR (D6-Me2SO)
 (ppm): 2.82 (s, 2  CH3), 3.43 and 3.66 (2t,
-CH2CH2-), 7.73 (s, H-4 and H-7). UV (H2O, pH
7.0): 256 (6300), 297 (12900), 306 (13300).
Elemental analysis: calculated for C11H13N3-
Cl2SHCl: C, 40.44; H, 4.33; N, 12.86. Found:
C, 40.31; H, 4.52; N, 12,73.
5,6-Dichloro-2-(diethylaminoeth-1-ylthio)ben-
zimidazole (4e): Similar to 4a, from 3d and
2-diethylaminoethylchloride hydrochloride:
(m.p. 266–269C, from H2O/EtOH, 81%);
1H
NMR (D6-Me2SO)  (ppm): 1.26 and 3.18 (t
and q, 2  C2H5), 3.35 and 3.61 (2t,
-CH2CH2-), 7.73 (s, H-4 and H-7). UV (H2O, pH
7.0): 256 (5800), 291 (13000), 297 (13300).
Elemental analysis: calculated for C13H17-
N3Cl2S: C, 49.06; H, 5.40; N, 13.21. Found: C,
49.30; H, 5.54; N, 13.43.
5,6-Dichloro-2-(dimethylaminoprop-1-ylthio)-
benzimidazole hydrochloride (4f): Similar to
4a, from 3d and 3-dimethylaminopropyl-
chloride hydrochloride. The crude product
was purified by column chromatography (sil-
ica gel, 3  15 cm) using CHCl3/MeOH
(80 :20) as an eluent. The product-containing
fractions were evaporated and the product
was transformed to the hydrochloride as de-
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scribed for 4c: (m.p. 219–222C, 56%); 1H
NMR (D6-Me2SO)  (ppm): 2.51 (s, 2  CH3),
2.15, 3.16 and 3.44 (2t and q, -CH2CH2CH2-),
7.76 (s, H-4 and H-7). UV (H2O, pH 7.0): 256
(6000), 297 (13100), 306 (13400). Elemental
analysis: calculated for C12H15N3Cl2SHCl:
C, 42.31; H, 4.74; N, 12.34. Found: C, 42.44;
H, 4.91; N, 12.48.
5,6-Dichloro-2-(morpholineth-1-yl)benzimida-
zole hydrochloride (4g): Similar to 4a, from 3d
and morpholineethyl-chloride hydrochloride.
The crude product was purified by column
chromatography as described for 4f and
transformed into the hydrochloride as de-
scribed for 4c: (m.p. 147–150C, 55%); 1H
NMR (D6-Me2SO)  (ppm): 3.20 and 3.73 (bs
and t, -CH2CH2-), 3.52 and 3.92 (t and bs,
CH2-morpholine), 7.73 (s, H-4 and H-7). UV
(H2O, pH 7.0): 256 (5900), 297 (13200), 306
(13500). Elemental analysis: calculated for
C13H15N3Cl2SHCl: C, 42.35; H, 4.38; N,
11.40. Found: C, 42.46; H, 4.52; N, 11.27.
5,6-Dichloro-2-(4-nitrobenzylthio)benzimida-
zole (4h): Similar to 4a, from 3d and
4-nitrobenzyl chloride: (m.p.134–138C, from
EtOH/H2O, 59%);
1H NMR (D6-Me2SO) 
(ppm): 4.70 (s, CH2), 7.60–8.10 (2m, H-arom.
and H-benzimidazole). UV (H2O/MeOH, 1:1):
265 (13400), 302 (17700), 308 (17100). Ele-
mental analysis: calculated for C14H9N3-
O2Cl2S : C, 47.48; H, 2.57; N, 11.87. Found: C,
47.40; H, 2.39; N, 11.70.
5,6-Dichloro-2-(3,4-dichlorobenzylthio)benzi-
midazole (4i): Similar to 4a, from 3d and
3,4-dichlorobenzyl chloride: (m.p.157–159C,
from EtOH/H2O, 39%);
1H NMR (D6-Me2SO)
 (ppm): 4.56 (s, CH2), 7.40–7.80 (m, H-arom.
and H-benzimidazole). UV (H2O/MeOH, 1:1):
263 (7300), 303 (16800), 310 (17000). Ele-
mental analysis: calculated for C14H8N2Cl4S:
C, 44.48; H, 2.14; N, 7.41. Found: C, 44.63; H,
2.26; N, 7.30.
5-Carboxy-2-allylthiobenzimidazole (4j): Simi-
lar to 4a, from 3j and allyl chloride using
NaOH instead of DBU: (from MeOH, 72%,
m.p. 112–115C); 1H NMR (D6-Me2SO) 
(ppm): 5.13 and 5.34 (2d, =CH2), 6.00 (m,
HC=), 7.52 and 7.78 (2dd, H-6 and H-7), 8.02
(s, H-4). UV (H2O/MeOH, 9:1): 225 (24500),
299 (14400). Elemental analysis: calculated
for C14H8N2Cl4SH2O: C, 52.37; H, 4.80; N,
11.11. Found: C, 52.29; H, 4.58; N, 11.14.
5-Carboxy-2-benzylthiobenzimidazole (4k):
Similar to 4j, from 3j and benzyl chloride:
(m.p. 131–134C, from MeOH, 64%); 1H NMR
(D6-Me2SO)  (ppm): 4.62 (s, CH2), 7.30–7.60
(m, H-arom.), 7.48 and 7.82 (2dd, H-6 and
H-7), 8.03 (s, H-4). UV (H2O /MeOH, 9:1): 224
(29800), 300 (14300). Elemental analysis: cal-
culated for C14H8N2Cl4SH2O: C, 63.37; H,
4.26; N, 9.86. Found: C, 63.30; H, 4.40; N,
9.81.
5-Carboxy-2-(4-nitrobenzylthio)benzimidazole
(4l): Similar to 4j, from 3j and 4-nitrobenzyl
chloride: (m.p. 283–286C, from MeOH, 68%);
1H NMR (D6-Me2SO)  (ppm): 4.69 (s, CH2),
7.20–8.20 (m, H-arom. and H-benzimidazole).
UV (H2O/MeOH, 1:1): 294 (18900). Elemen-
tal analysis: calculated for C15H11N3SO4: C,
54.71; H, 3.37; N, 12.76. Found: C, 54.89; H,
3.44; N, 12.62.
5-Carboxy-2-(3,4-dichlorobenzylthio)benzimi-
dazole (4m): Similar to 4j, from 3j and
3,4-dichlorobenzylchloride: (m.p. 284–288C,
from MeOH, 73%); 1H NMR (D6-Me2SO) 
(ppm): 4.64 (s, CH2), 7.40–7.85 (m, H-arom.,
H-6 and H-7), 8.05 (s, H-4). UV (H2O/MeOH,
1:1): 229 (36600), 302 (15400). Elemental
analysis: calculated for C15H10N2SCl2O2
H2O: C, 48.53; H, 3.26; N, 7.55. Found: C,
47.41; H, 3.08; N, 7.31.
4,6-Dichloro-2-thiobenzimidazole (6): 1.168 g
(6.6 mmol) of 1,3-dichloro-4,5-diaminoben-
zene (5) was dissolved in a mixture of EtOH
(13 ml) and water (2 ml), followed by the addi-
tion of 0.8 ml (13.2 mmol) of carbon disulfide
and 1.48 g (26.4 mmol) of KOH. The solution
was stirred under reflux for 2 h, decolorized
with charcoal and brought to pH 5 with acetic
acid. The yellowish chromatographic pure
precipitate was removed by filtration. Yield
0.9 g (62%). A small amount for analysis was
crystallized from water: (m.p. > 300C). 1H
NMR (D6-Me2SO)  (ppm): 7.12 and 7.32 (2dd,
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H-5 and H-7). UV (H2O, pH 7): 230 (12100),
251 (16300), 314 (17900). Elemental analy-
sis: calculated for C7H4N2Cl2S: C, 38.38; H,
1.84; N, 12.79. Found: C, 38.28; H, 1.95; N,
12.62.
4,6-Dichloro-2-(dimethylaminoeth-1-yl)benzi-
midazole hydrochloride (4n): Similar to 4a,
from 6 and 2-dimethylaminoethyl chloride hy-
drochloride. The crude product was purified
by column chromatography as described for
4f, and transformed into the hydrochloride as
described for 4c: (m.p. 230–233C, 38%); 1H
NMR (D6-Me2SO)  (ppm): 2.84 (s, 2  CH3),
3.46 and 3.69 (2t, -CH2CH2-), 7.77 and 7.51
(2d, H-5 and H-7). UV (H2O, pH 7): 257 (6700),
291 (12300), 299 (12600). Elemental analy-
sis: calculated for C11H13N3SCl22H2OHCl:
C, 36.43; H, 5.01; N, 11.58. Found: C, 36.40;
H, 4.81; N, 11.45.
4,6-Dichloro-2-(4-nitrobenzylthio)benzimida-
zole (4o): Similar to 4a, from 6 and
4-nitrobenzylchloride (m.p. 132–134C from
EtOH/ H2O, 41%),
1H NMR (D6-Me2SO) 
(ppm): 4.71 (s, CH2), 7.20–8.20 (m, H-arom.
and H-benzimidazole). UV (H2O/MeOH, 1:1):
260 (16100), 303 (17800). Elemental analy-
sis: calculated for C14H9N3O2Cl2S: C, 47.48;
H, 2.57; N, 11.87. Found: C, 47.41; H, 2.39; N,
11.69.
RESULTS AND DISCUSSION
Chemical synthesis
In order to expand the group of benzi-
midazole derivatives, we synthesised several
new benzimidazole ring-containing com-
pounds. In addition to the earlier reported
5,6-dinitro- and 4,6-dinitrobenzimidazoles,
their nucleosides and 5,6-dinitro-2-trifluoro-
methylbenzimidazole [17, 18], we have under-
taken the synthesis of a series of 1-substituted
5,6-dinitrobenzimidazoles (2a–f) by alkyl-
ation of 5,6-dinitrobenzimidazole (1) with ap-
propriate halogenoalkylamine in acetonitrile
using 1,8-diazabicyclo[5,4,0]undec-7-en (DBU)
as a base. Additionally, 5,6-dinitro-1-(2,3-di-
hydroxyprop-1-yl)benzimidazole (2g) was ob-
tained in the reaction of 1 with glycitole under
the same reaction conditions (Scheme 1). The
choice of 1-substituents was motivated by
their presence in numerous drugs showing a
variety of antimicrobial, psychostimulant and
other activities.
The second series were sulfur-substituted de-
rivatives of a modified benzimidazole nucleus.
The methyl-, chlorine- and carboxy-substi-
tuted derivatives of 2-thiobenzimidazoles
(3a–m) were S-alkylated with halogenoalkyl-
amines, allyl chloride, or benzyl chloride and
its p-nitro and 3,4-dichlorosubstituted deriva-
tives to provide the corresponding derivatives
(4a–o). The substrates 3a–m were previously
synthesised by the reaction of carbon
disulfide with the corresponding phenyl-
enediamine [6]. The novel 4,6-dichloro-2-thio-
benzimidazole (6) was similarly prepared by
treating 1,3-dichloro-4,5-diaminobenzene (5)
with carbon disulfide (Scheme 2). The result-
ing derivatives were purified by crystalliza-
tion or flash column chromatography. In a few
cases it was necessary to transform the prod-
ucts into their respective hydrochlorides to
obtain a crystalline material. Of the N- and
S-substituted derivatives shown in Schemes 1
and 2, only 3c has been previously mentioned
in the patent literature [19].
Antibacterial activity
The antibacterial activity of the benzi-
midazole derivatives was first tested by the
agar disc-diffusion method against Gram-posi-
tive and Gram-negative bacteria. The results
of these studies are summarized in Table 1.
The compounds not shown in the table had no
antibacterial activity. The new benzimidazole
derivatives reported here, particulary 4d–4n,
are approximately as active as metronidazole
used as a control substance. In the case of
enterobacteria, such as E. coli and P. vulgaris,
the bezimidazoles 4d–4n exhibited moderate
activity, whereas metronidazole was inactive.
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On the other hand, metronidazole was more
active against bacilli then 2g and 4a–f and
4n.
More attention was devoted to the investiga-
tion of antibacterial activity against Steno-
trophomonas maltophilia strains. S. malto-
philia (previously called Pseudomonas malto-
philia and Xanthomonas maltophilia) is an in-
creasingly recognized nosocomial pathogen,
particularily for immunocompromised pa-
tients. Risk factors for S. maltophilia are colo-
nization and infection due to mechanical ven-
tilation, previous exposure to broad spectrum
antibiotics, fungal infections, catheterization,
prolonged hospitalization and the use of
equipment contacting with the respiratory
tract, such as nebulizers. S. maltophilia is
found in a wide variety of ageratic, soil, and
rhizosphere environments and on various
contaminated materials and fomites, includ-
ing faucets, showers, ice-making machines
etc. Several of these have been implicated as
sources of nosocomial infections with S. mal-
tophilia. With the exception of trimeto-
prim-sulfamethoxazole (Biseptol, Cotrimo-
razole), many post-therapy isolates of S.
maltophilia quickly become resistant to
antimicrobial agents [20]. The tests presented
here (Table 2) show that only compounds 4d,
4e, 4f and 4n, which are inactive against stan-
dard and nosocomial strains of B. cepacia and
P. aeruginosa, were active against nosocomial
strains of S. maltophilia. Compounds 4f and
4n displayed antibacterial activity also
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Scheme 1
against the standard strain of S. maltophilia
NCTC 13637 (MIC 400 and 200 g/ml, respec-
tively). Derivatives 4d and 4e — inactive
against standard strains of Pseudomonas fam-
ily — are active against all of nosocomial
strains of S. maltophilia (MIC 50–400 g/ml)
tested here. In contrast, compounds 4f and
4n moderately active against standard
strains, were inactive against 49 and 16
nosocomial strains.
The results obtained indicate that the com-
pounds studied here or their possible struc-
tural analogues could be potential chemo-
therapeutics in the case of S. maltophilia infec-
tion. It is noteworthy that the nosocomial
S. maltophilia strains examined here were re-
sistant to -lactam antibiotics, including
penems, azeotronams and cephalosporins of
the 3rd generation and showed considerable
resistance to aminoglycosides and quinolones.
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Scheme 2
Anti-protozoal activity
Drugs (0.1 M) dissolved in dimethyl for-
mamide (DMF) were used in microtitre plate
susceptibility assays as previously described
[16]. In a few cases (2c, 4f, 4c, 4n) the com-
pounds required mild heat for dissolution. 4e
was soluble at 10 mM and 4h crystallized in
the assays at > 100 M. MIC values for 1,
2a–2g and 4a–o were estimated as previ-
ously described and only compounds with
MICs < 100 M in any assay are presented in
Table 2. The MIC values for metronidazole
(Mz) and albendazole (Alb) are also presented.
While neither of the compounds was uni-
formly as effective as metronidazole, or as ef-
fective as albendazole against Giardia, several
compounds had MIC values which should en-
courage further development as lead com-
pounds in a search for new anti-anaerobic
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Table 1. Antimicrobial activity of substituted benzimidazoles against Gram-positive and
Gram-negative bacteria strains
Bacteria strain
Diameter of growth inhibition area (mm)
Compound
2g 4a 4b 4c 4d 4e 4f 4n
Metroni-
dazole
S. aureus ATCC 6538P
S. aureus ATCC 25923
S. aureus NCTC 4163
M. flavus NCIB 8166
B. subtilis ATCC 6633
B. stenothermophilus ATCC 7953
B. cereus ML 98
E. coli NCTC 8196
P. vulgaris NCTC 4635
0
trace
0
12
17
14
14
0
0
trace
11
trace
11
11
11
trace
0
trace
trace
trace
0
trace
0
0
trace
0
trace
0
trace
0
trace
11
12
11
0
trace
12
12
11
trace
11
11
12
11
13
12
14
12
0
11
13
13
11
11
14
12
12
10
12
13
12
12
12
15
14
11
10
14
12
14
12
12
11
12
11
12
32
30
15
0
0
Table 2. Drug susceptibility assay of Pseudomonas family bacteria
Bacteria strain
MIC values (mg/ml)
Compound
4d 4e 4f 4n
S. maltophilia ATCC 13637 >400 >400 400 200
B. cepacia ATCC 25416 >400 >400 >400 >400
P. aeruginosa ATCC 27863 >400 >400 >400 >400
P. aeruginosa ATCC 15442 >400 >400 >400 >400
P. aeruginosa NCTC 6749 >400 >400 >400 >400
S. maltophilia 67 clinical
strains
100
— 3 strains
100–200
— 35 strains
300–400
— 29 strains
50
–2 strains
100–200
— 28 strains
300–400
— 37 strains
100
— 2 strains
200
— 4 strains
400
— 12 strains
>400
— 49 strains
100
— 2 strains
200
–5 strains
400
— 44 strains
>400
— 16 strains
Metronidazole used as control substance; MIC > 400 (g/ml); replica plates method was employed.
protozoal clinical agents. Compounds 2a, 2b,
2c, and to a lesser extent 2e, were the most ef-
fective against T. vaginalis. These 5,6-dini-
tro-1-(aminoethyl)benzimidazoles may act via
reduction of the nitro group via ferredoxin in
the same way metronidazole acts, but not as
inhibitors of tubulin polymerization as alben-
dazole does, since the metronidazole-resistant
line F1623-M1 was not susceptible to these
compounds. This is what is expected of drugs
with a similar mechanism of action to metro-
nidazole.
The compound 4h and to a lesser extent 4o
were the most effective against Giardia and
Entamoeba. While 5,6-dichloro and 4,6-di-
chloro benzimidazoles carry a nitrobenzyl
group, the mechanism of action may not be
via the nitro group, since the metro-
nidazole-resistant Giardia lines and the par-
ent isolates were similarly susceptible. In ad-
dition, the MIC of 4h against Entamoeba was
the same as that of metronidazole. Compound
4l which also carries the nitrobenzyl group
but is a 5-carboxybenzimidazole, rather than a
dichloro-benzimidazole, was ineffective in all
assays suggesting that the nitrobenzyl group
was not the all-important functional moiety in
4h and 4o. Since benzimidazole compounds
have not previously been shown to be effective
against Entamoeba and in our hands
albendazole is ineffective against Tricho-
monas (Table 3), our results, particularly
those for 4h, are worth pursuing in the search
for new effective anti-protozoal drugs.
We would like to thank Raymond Campbell
for his expert technical assistance in carrying
out the drug susceptibility assays
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